AVE
vs
S
S&P/ASX 300
AVE
Over the past 12 months, AVE has significantly outperformed S&P/ASX 300, delivering a return of +233% compared to the S&P/ASX 300's +6% growth.
Stocks Performance
AVE vs S&P/ASX 300
Performance Gap
AVE vs S&P/ASX 300
Performance By Year
AVE vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Avecho Biotechnology Ltd
Glance View
Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, and Veterinary Applications. The firm's segments include Production and Personal Care and Human Health. The Production and Personal Care segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches. The Human Health segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
